Form 4: ORIC CFO Reports Routine Stock Transactions

Oric Pharmaceuticals' CFO, Dominic Piscitelli, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported transactions involving the company's common stock.
• On December 15, 2025, 29,333 shares of common stock were acquired at a price of $0 due to the vesting of restricted stock units (RSUs).
• This acquisition included 8,000 RSUs from an award vesting 1/3 annually from December 15, 2023, 10,000 RSUs from an award vesting 1/3 annually from December 15, 2024, and 11,333 RSUs from an award vesting 1/3 annually from December 15, 2025.
• On December 16, 2025, 10,720 shares of common stock were sold at a weighted average price of $9.0604 per share, ranging from $9.0396 to $9.1953.
• This sale was specifically to cover tax withholding obligations related to the RSU vesting and was not a discretionary sale by the reporting person.
• Following these transactions, the reporting person's direct beneficial ownership of common stock decreased to 68,148 shares.
• The reported beneficial ownership also includes 1,218 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.
• Remaining unvested RSUs beneficially owned by the reporting person total 32,667.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation vesting and subsequent tax-related sales, which are pre-scheduled and non-discretionary. This type of filing typically has a neutral impact on market sentiment as it does not reflect a change in management's discretionary view of the company's prospects.

Positives

• Vesting of 29,333 restricted stock units indicates continued performance and retention of the Chief Financial Officer, aligning executive incentives with shareholder interests.

Negatives

• A sale of 10,720 shares, even for tax purposes, reduces the direct equity stake of the Chief Financial Officer in the company, which could be misinterpreted by some investors.

Risks

• The sale of shares by an insider, even when explicitly stated as being for tax withholding and non-discretionary, could be misinterpreted by the market as a lack of confidence, potentially leading to negative short-term sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction report is a routine disclosure for publicly traded companies and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard executive compensation practices within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across various industries, including biotechnology and pharmaceuticals, aligning executive incentives with long-term shareholder value.
• The sale of shares to cover tax withholding obligations upon RSU vesting is a standard and expected procedure for executives receiving equity compensation, consistent with practices observed in comparable companies.

Stakeholder Impact

• Shareholders: Minor impact. Routine insider transactions do not typically signal a change in company fundamentals or management's discretionary outlook. The sale for tax purposes is a common occurrence and does not reflect a lack of confidence.
• Employees: No direct impact. The RSU vesting is part of executive compensation, which is standard practice and contributes to executive retention.

Next Steps

• Future vesting of remaining restricted stock units on December 15, 2026, and December 15, 2027, as per the original award schedules.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions related to the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations. Such transactions do not reflect a change in the company's fundamental performance or management's discretionary view of future prospects. Therefore, the filing itself does not provide a basis for a change in investment recommendation; a 'hold' stance is maintained, pending further operational or strategic updates.

Keywords

ORIC, Oric Pharmaceuticals, Form 4, Insider Transaction, CFO, Dominic Piscitelli, Restricted Stock Units, RSU Vesting, Equity Compensation, Tax Withholding